Skip to main navigation Skip to search Skip to main content

INHALE 1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in combination with a Basil Insul

Project: Research

Project Details

StatusFinished
Effective start/end date02/7/22 → 04/30/26

Funding

  • Jaeb Center for Health Research Incorporated: $77,573.02